The 12 Hallmarks of Aging in Dogs, Explained
Read full insightOndansetron for Cats: Nausea Control and Safety
By La Petite Labs Editorial 13 min read
References
Numbered references identify the sources used for specific claims. Read the study design, species and evidence boundaries alongside each finding.
-
Lauren R Forsythe, Rania Gollakner. Ondansetron. Study design/context: VCA/LifeLearn veterinary client guidance for dogs and cats, not a study measuring feline incidence.Evidence boundary: VCA provides veterinary client guidance for dogs and cats, rather than measured feline side-effect frequencies.↩ 1 · ↩ 2 · ↩ 3 · ↩ 4 · ↩ 5 · ↩ 6
-
Samantha Taylor, Daniel L Chan, et al. 2022 ISFM Consensus Guidelines on Management of the Inappetent Hospitalised Cat. Study design/context: Veterinary consensus based on literature and expert clinical experience for hospitalised cats; not one treatment trial.Species/context: catEvidence boundary: These consensus guidelines address hospitalised cats with poor intake.↩ 1 · ↩ 2 · ↩ 3 · ↩ 4 · ↩ 5
-
Ayşe Gölgeli Bedir, Latif Emrah Yanmaz, et al. The Effect of Maropitant, Ondansetron and Metoclopramide on Dexmedetomidine-Induced Vomiting in Cats. Study design/context: Sixty-four healthy cats undergoing elective castration; randomized four groups of 16. Ondansetron or metoclopramide IM, maropitant or saline SC, 30 minutes before dexmedetomidine; blinded 30-minute observation.Species/context: catEvidence boundary: The experiment tested injected medicines in healthy cats before sedation.↩ 1 · ↩ 2 · ↩ 3
-
J M Quimby, R C Lake, et al. Oral, subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats. Study design/context: Six healthy research cats received single oral, subcutaneous and intravenous administrations in a crossover design, with serial blood sampling and noncompartmental pharmacokinetic analysis.Species/context: catEvidence boundary: Researchers measured blood exposure in six healthy cats, rather than clinical treatment outcomes.↩ 1 · ↩ 2
-
R L Fitzpatrick, L A Wittenburg, et al. Limited sampling pharmacokinetics of subcutaneous ondansetron in healthy geriatric cats, cats with chronic kidney disease, and cats with liver disease. Study design/context: Sixty cats in geriatric, CKD and liver-disease groups; one subcutaneous administration. Blood at 30 and 120 minutes fed a limited-sampling exposure model.Species/context: catEvidence boundary: The study estimated blood exposure after an under-the-skin injection in older cats and cats with disease.↩
-
Lara B Zajic, Andrea K Herndon, et al. Assessment of absorption of transdermal ondansetron in normal research cats. Study design/context: Five healthy research cats received compounded Lipoderm ondansetron on the inner ear, once and once daily for five days in separate phases. Serum was analyzed by LC-MS/MS.Species/context: catEvidence boundary: Researchers tested absorption of one compounded ear preparation in five healthy cats.↩ 1 · ↩ 2
-
Advanced Rx of Tennessee, LLC. Ondansetron orally disintegrating tablets: prescribing information. Study design/context: Human ODT prescribing information; not a feline trial or cat dose label.Species/context: humanEvidence boundary: This is human prescribing information; feline prescribing and dosing are separate decisions.↩ 1 · ↩ 2 · ↩ 3
Keep exploring
What would you like to understand next?
Search practical guides about healthy aging, cellular energy, ingredients, and daily support for cats.